Intravenous Immunoglobulin Treatment and Screening for Hypocretin Neuron-Specific Autoantibodies in Recent Onset Childhood Narcolepsy with Cataplexy

Abstract

Background: Narcolepsy with cataplexy (NC) is caused by substantial loss of hypocretin neurons. NC patients carry the HLA-DQB1*0602 allele suggesting that hypocretin neuron loss is due to an autoimmune attack. We tested intravenous immunoglobulin (IVIG) treatment in early onset NC.

Methods: 2 NC children received IVIG 1 g/kg/day in 2 days/month, 5 times, at 3 and 6 months disease duration, respectively. CSF and serum were analysed for hypocretin neuron autoantibodies. An association between disease duration and IVIG effect was calculated in all published NC cases.

Results: Autoantibodies were not detectable. Cataplexy improved in both children but only temporarily in one patient. Subjective sleepiness temporarily improved, sleep paralysis emerged and hypnagogic hallucinations and REM sleep behaviour disorder worsened in one child. Sleep parameters and CSF hypocretin-1 remained abnormal. On a group level, IVIG treatment ≤9 months from disease duration predicted reduction of cataplexy (p=0.004) and sleepiness (p=0.066). Sleep parameters and CSF hypocretin-1 levels were unchanged except if treated extremely early.

Conclusion: IVIG treatment initiated before 9 months disease duration has some clinical efficiency. The unaffected CSF hypocretin-1 levels and lack of autoantibodies suggest that any autoimmune process occurs very early in NC. The final IVIG effect needs to be investigated in a placebo-controlled study.

Key words

narcolepsy with cataplexy - autoantibodies - CSF hypocretin-1 - IVIG

References

• 1 Mignot E. Genetic and familial aspects of narcolepsy.  Neurology. 1998;  50 S16-S22
• 2 American Academy of Sleep Medicine (AASM) . International Classification of Sleep Disorders (ICSD), 2nd edition 2005 2008; 
• 3 Jennum P, Knudsen S, Kjellberg J. The economic consequences of narcolepsy.  J Clin Sleep Med. 2009;  5 240-245
• 4 Peyron C, Faraco J, Rogers W. et al . A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains.  Nat Med. 2000;  6 991-997
• 5 Thannickal TC, Moore RY, Nienhuis R. et al . Reduced number of hypocretin neurons in human narcolepsy.  Neuron. 2000;  27 469-474
• 6 Knudsen S, Jennum P, Alving J. et al . Validation of the ICSD-2 Criteria for CSF hypocretin-1 measurements in the diagnosis of narcolepsy in the Danish population.  Sleep. 2010;  33 169-176
• 7 Knudsen S, Mikkelsen JD, Jennum P. Antibodies in narcolepsy-cataplexy patient serum bind to rat hypocretin neurons.  Neuroreport. 2007;  18 77-79
• 8 Martinez-Rodriguez JE, Sabater L, Graus F. et al . Evaluation of hypothalamic-specific autoimmunity in patients with narcolepsy.  Sleep. 2007;  30 27-28
• 9 Overeem S, Verschuuren JJ, Fronczek R. et al . Immunohistochemical screening for autoantibodies against lateral hypothalamic neurons in human narcolepsy.  J Neuroimmunol. 2006;  174 187-191
• 10 Black III JL, Silber MH, Krahn LE. et al . Analysis of hypocretin (orexin) antibodies in patients with narcolepsy.  Sleep. 2005;  28 427-431
• 11 Tanaka S, Honda Y, Inoue Y. et al . Detection of autoantibodies against hypocretin, hcrtrl, and hcrtr2 in narcolepsy: anti-Hcrt system antibody in narcolepsy.  Sleep. 2006;  29 633-638
• 12 Black III JL, Krahn LE, Pankratz VS. et al . Search for neuron-specific and nonneuron-specific antibodies in narcoleptic patients with and without HLA DQB1*0602.  Sleep. 2002;  25 719-723
• 13 Smith AJ, Jackson MW, Neufing P. et al . A functional autoantibody in narcolepsy.  Lancet. 2004;  364 2122-2124
• 14 Jackson MW, Reed JH, Smith AJ. et al . An autoantibody in narcolepsy disrupts colonic migrating motor complexes.  J Neurosci. 2008;  28 13303-13309
• 15 Peyron C, Tighe DK, van den Pol AN. et al . Neurons containing hypocretin (orexin) project to multiple neuronal systems.  J Neurosci. 1998;  18 9996-10015
• 16 Hallmayer J, Faraco J, Lin L. et al . Narcolepsy is strongly associated with the T-cell receptor alpha locus.  Nat Genet. 2009;  41 708-711
• 17 Aran A, Lin L, Nevsimalova S. et al . Elevated anti-streptococcal antibodies in patients with recent narcolepsy onset.  Sleep. 2009;  32 979-983
• 18 Cvetkovic-Lopes V, Bayer L, Dorsaz S. et al . Elevated Tribbles homolog 2-specific antibody levels in narcolepsy patients.  J Clin Invest. 2010;  120 713-719
• 19 Dauvilliers Y, Carlander B, Rivier F. et al . Successful management of cataplexy with intravenous immunoglobulins at narcolepsy onset.  Ann Neurol. 2004;  56 905-908
• 20 Dauvilliers Y. Follow-up of 4 narcolepsy patients treated with intravenous immunoglobulins.  Ann Neurol. 2006;  60 153
• 21 Dauvilliers Y, Abril B, Mas E. et al . Normalization of hypocretin-1 in narcolepsy after intravenous immunoglobulin treatment.  Neurology. 2009;  73 1333-1334
• 22 Lecendreux M, Maret S, Bassetti C. et al . Clinical efficacy of high-dose intravenous immunoglobulins near the onset of narcolepsy in a 10-year-old boy.  J Sleep Res. 2003;  12 347-348
• 23 Valko PO, Khatami R, Baumann CR. et al . No persistent effect of intravenous immunoglobulins in patients with narcolepsy with cataplexy.  J Neurol. 2008;  255 1900-1903
• 24 Hecht M, Lin L, Kushida CA. et al . Report of a case of immunosuppression with prednisone in an 8-year-old boy with an acute onset of hypocretin-deficiency narcolepsy.  Sleep. 2003;  26 809-810
• 25 Plazzi G, Poli F, Franceschini C. et al . Intravenous high-dose immunoglobulin treatment in recent onset childhood narcolepsy with cataplexy.  J Neurol. 2008;  255 1549-1554
• 26 Chen W, Black J, Call P. et al . Late-onset narcolepsy presenting as rapidly progressing muscle weakness: response to plasmapheresis.  Ann Neurol. 2005;  58 489-490
• 27 Fronczek R, Verschuuren J, Lammers GJ. Response to intravenous immunoglobulins and placebo in a patient with narcolepsy with cataplexy.  J Neurol. 2007;  254 1607-1608

Correspondence